Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume → Did Intel Just Dethrone Nvidia? (From Chaikin Analytics) (Ad) Free AKBA Stock Alerts $1.23 -0.06 (-4.65%) (As of 04:30 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics Short Interest DataCurrent Short Volume11,860,000 sharesPrevious Short Volume13,690,000 sharesChange Vs. Previous Month-13.37%Dollar Volume Sold Short$14.94 millionShort Interest Ratio / Days to Cover2.4Last Record DateApril 30, 2024Outstanding Shares209,600,000 sharesPercentage of Shares Shorted5.66%Today's Trading Volume2,202,337 sharesAverage Trading Volume4,122,846 sharesToday's Volume Vs. Average53% Short Selling Akebia Therapeutics ? Sign up to receive the latest short interest report for Akebia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAKBA Short Interest Over TimeAKBA Days to Cover Over TimeAKBA Percentage of Float Shorted Over Time Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. Akebia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202411,860,000 shares $14.94 million -13.4%N/A2.4 $1.26 4/15/202413,690,000 shares $19.03 million +2.2%N/A2.9 $1.39 3/31/202413,400,000 shares $24.52 million +32.3%N/A3 $1.83 3/15/202410,130,000 shares $17.22 million +24.9%N/A3.4 $1.70 2/29/20248,110,000 shares $12.81 million +1.4%N/A4 $1.58 2/15/20248,000,000 shares $11.76 million -8.9%N/A4.5 $1.47 Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20248,780,000 shares $14.75 million +12.1%N/A5.4 $1.68 1/15/20247,830,000 shares $12.14 million -0.5%N/A5 $1.55 12/31/20237,870,000 shares $9.76 million +7.4%N/A5.3 $1.24 12/15/20237,330,000 shares $8.43 million -18.7%N/A5.5 $1.15 11/30/20239,010,000 shares $9.55 million -8.8%N/A6.9 $1.06 11/15/20239,880,000 shares $9.88 million -4.3%N/A6.8 $1.00 10/31/202310,320,000 shares $9.08 million +33.2%N/A6.8 $0.88 10/15/20237,750,000 shares $7.03 million +6.5%N/A4.5 $0.91 9/30/20237,280,000 shares $8.30 million +0.7%N/A4.4 $1.14 9/15/20237,230,000 shares $9.11 million +24.4%N/A4.1 $1.26 8/31/20235,810,000 shares $8.08 million -14.1%N/A3.1 $1.39 8/15/20236,760,000 shares $8.86 million +10.3%N/A3.2 $1.31 7/31/20236,130,000 shares $10.24 million +13.7%N/A2.8 $1.67 7/15/20235,390,000 shares $5.71 million +11.4%N/A2.9 $1.06 6/30/20234,840,000 shares $4.43 million +11.3%N/A2.7 $0.92 6/15/20234,350,000 shares $4.96 million -15.5%N/A2.5 $1.14 5/31/20235,150,000 shares $5.36 million +26.5%N/A3 $1.04 5/15/20234,070,000 shares $4.44 million -9.6%N/A2.4 $1.09 4/30/20234,500,000 shares $4.09 million -20.8%N/A2.4 $0.91 4/15/20235,680,000 shares $3.57 million +0.4%N/A2.9 $0.63 3/31/20235,660,000 shares $3.17 million -15.3%N/A2.8 $0.56 3/15/20236,680,000 shares $4.49 million -20.3%N/A3 $0.67 2/28/20238,380,000 shares $7.06 million +82.6%N/A3.5 $0.84 2/15/20234,590,000 shares $4.07 million +38.3%N/A2 $0.89 1/31/20233,320,000 shares $2.09 million -28.1%N/A1.7 $0.63 1/15/20234,620,000 shares $3.21 million -0.9%N/A2.7 $0.70 12/30/20224,660,000 shares $2.69 million -0.4%N/A2.7 $0.58 12/15/20224,680,000 shares $2.12 million -2.9%N/A3.1 $0.45 11/30/20224,820,000 shares $1.30 million -12.5%N/A3.4 $0.27 11/15/20225,510,000 shares $1.41 million -6.9%N/A3.8 $0.26 10/31/20225,920,000 shares $1.51 million -5.9%N/A3.4 $0.25 10/15/20226,290,000 shares $1.82 million -13.4%N/A2.7 $0.29 9/30/20227,260,000 shares $2.30 million -5.8%N/A2.6 $0.32 9/15/20227,710,000 shares $2.85 million -3.5%N/A1.1 $0.37Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. AKBA Short Interest - Frequently Asked Questions What is Akebia Therapeutics' current short interest? Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 11,860,000 shares of AKBA short. Learn More on Akebia Therapeutics' current short interest. What is a good short interest ratio for Akebia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 2.0. Learn More on Akebia Therapeutics's short interest ratio. Which institutional investors are shorting Akebia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Akebia Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Akebia Therapeutics' short interest increasing or decreasing? Akebia Therapeutics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 11,860,000 shares, a decrease of 13.4% from the previous total of 13,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akebia Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Akebia Therapeutics: Verastem, Inc. (3.49%), XOMA Co. (2.33%), Inozyme Pharma, Inc. (8.23%), ESSA Pharma Inc. (2.09%), Nanobiotix S.A. (0.12%), Eliem Therapeutics, Inc. (0.31%), RAPT Therapeutics, Inc. (9.23%), XBiotech Inc. (3.88%), Xeris Biopharma Holdings, Inc. (6.50%), Aquestive Therapeutics, Inc. (5.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Akebia Therapeutics stock? Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akebia Therapeutics? A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further. How often is Akebia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: VSTM Short Interest Data XOMA Short Interest Data INZY Short Interest Data EPIX Short Interest Data NBTX Short Interest Data ELYM Short Interest Data RAPT Short Interest Data XBIT Short Interest Data XERS Short Interest Data AQST Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKBA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity